AURKA and melanoma: Although in preclinical investigations, several Aurora kinases inhibitors, such as MLN8054, PHA-739358, VE-465, ZM447439, SNS-314 and JNJ-7706621, have been utilized in preclinical studies on melanoma models, demonstrating to inhibit cell proliferation, to induce apoptosis, and to inhibit cell migration in melanoma as respect to melanocytes [13-17], only one Aurora A kinase inhibitor (MLN8237) is in a Phase II clinical trials for patients with unrespectable Stage III-IV melanoma (clinicaltrials.gov).